Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT06449833

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06449833
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06449833. Randomized; double masking; primary purpose treatment. Start 2024-06 (anticipated); primary completion 2026-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
Acronym
HHTN
Condition
Type2 Diabetes Mellitus
Condition
Nonalcoholic Fatty Liver Disease
Intervention (Drug)
Henagliflozein and Metformin
Intervention (Drug)
Linagliptin and Metformin
Lead sponsor
Zhujiang Hospital (class: other)

Record details

Record id
cardio:ct-nct06449833
Content hash
e49e365028bc595529f82f8ec8ddff2fa24d2f322c6d7128ab9a5c8ebe5f3aae